Alice Bradford received ECT for postpartum depression, suffered severe complications, and died not long after. Her case highlights the need for better reporting, oversight, and patient protections.
Theresa had 32 ECT sessions in 1989 and experienced severe memory loss, cognitive problems, and a decline in her quality of life. Her letter to the FDA (Docket #82P-0316) urges the FDA to keep the ECT device at class III.
The America Psychiatric Association (APA) advocated against mandatory neuropsychological testing in the 2016 ECT device reclassification.
Exerpts from ECT recipeints submissions the 1990 FDA dockets.
This spring, Life After ECT launched a comprehensive FDA reporting guide for injured electroconvulsive therapy (ECT) recipients. This post is a progress update and an overview of our future reporting goals.
Moira Dolan MD to the FDA regarding ECT draft guidance for the 2016 electroshock device risk reclassifacation.